Table 2.
Summary of covariates included in stepwise covariate analysis
| Covariate | Range or N (%) a | Median b | % Missing | Stepwise covariate model | |||
|---|---|---|---|---|---|---|---|
| Clearance | Central volume | ||||||
| Inclusion | P value c | Inclusion | P value | ||||
| Age, y | 15–94 | 62 | 0 | No | 0.246 | No | 0.95 |
| Sex | 0 | Yes | <0.0001 | Yes | <0.0001 | ||
| Male | 1,293 (59.1) | NE | |||||
| Female | 895 (40.9) | ||||||
| Cancer type | 0 | Yes | <0.0001 | No | 0.896 | ||
| Melanoma | 1,612 (73.7) | ||||||
| NSCLC | 554 (25.3) | NE | |||||
| Other cancer type | 22 (1.01) | ||||||
| ECOG‐PS | 0.2 | Yes | <0.0001 | No | 0.366 | ||
| 0 (asymptomatic) | 1,256 (57.4) | ||||||
| 1 (symptomatic) | 927 (42.4) | NE | |||||
| Tumor burden, mm | 10–895 | 86 | 11.2 | Yes | <0.0001 | No | 0.0557 |
| IPI status | 26.4 | Yes | <0.0001 | Yes | <0.0001 | ||
| IPI‐naive | 856 (39.1) | ||||||
| IPI‐treated | 755 (34.5) | NE | |||||
| eGFR, mL/min/1.73 m2 | 25.4–403.0 | 88.7 | 1.2 | Yes | <0.0001 | No | 0.173 |
| Bilirubin, μmL/L | 1–87.2 | 8.55 | 1.6 | No | 0.0028 | No | 0.113 |
| AST, IUL | 5–197 | 21 | 1.6 | No | 0.0405 | No | 0.176 |
| ALB, g/L | 15–59 | 40 | 1.8 | Yes | <0.0001 | Yes | 0.0004 |
| Coadministered GCs | 0 | No | 0.358 | No | 0.037 | ||
| Yes | 326 (14.9) | ||||||
| No | 1,862 (85.1) | NE | |||||
ALB, albumin; AST, aspartate aminotransferase; ECOG‐PS, Eastern Cooperative Oncology Group‐Performance Status; eGFR, estimated glomerular filtration rate; GCs, glucocorticoids; IPI, ipilimumab; NE, not evaluated; NSCLC, non‐small cell lung cancer.
aRange (min‐max) is presented for continuous covariates and number of subjects and percentage of total for each category for categorical covariates. bMedian are included only for continuous covariates. cLast P value from stepwise covariate method is reported. All P values are from forward inclusion expected for bilirubin, which is from backward elimination. Bilirubin is the only covariate that was removed during the backward elimination.